Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesDose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer
Journal of Thoracic Oncology, 07/01/09
Kepka L et al. - In a trial to determine the efficacy of accelerated hypofractionated 3-dimensional conformal radiotherapy (3D-CRT) with dose-per-fraction escalation for treatment of stage III non-small cell lung cancer (NSCLC), it appears that although dose escalation with accelerated hypofractionated 3D-CRT was limited, results and toxicity profiles obtained using this technique are promising.
Methods- 173 pts with stage III NSCLC were treated using accelerated 3D-CRT and the simultaneous boost technique.
- The total dose of 56.7 Gy (including 39.9 Gy to elective area) was delivered over 4 wks in fractions of 2.7 Gy (1.9 Gy to elective area).
- Dose-per-fraction escalation study commenced after the outcomes of 70 pts had been evaluated.
- Dose per fraction was increased from 2.7 through 2.8 Gy (level 1 escalation) to 2.9 Gy (level 2 escalation); total dose increased, respectively, from 56.7 Gy through 58.8 Gy to 60.9 Gy.
- Dose to the elective area and overall treatment time remained unchanged.
- Fit pts received 2 to 3 courses of chemotherapy before radiotherapy.
- 2- and 3-yr overall survival rates were 32% and 19%, respectively.
- Of the pts, 7% had grade III acute esophageal toxicity and 6% had grade III or greater late pulmonary toxicity.
- 2 of 9 pts who received level 2 escalation (60.9 Gy) died of pulmonary toxicity.
- The study was terminated at a dose of 58.8 Gy; this schema was adopted as institutional policy for treatment of stage III NSCLC.
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Sponsor
Article Search
Sponsor